Brandon Wustman
23Patents
6h-index
20Co-inventors
65Inventor score
Filing activity: Jun 8, 2006 → Sep 16, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9056101B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | Human Necessities | 65 | Active |
| US8592362B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 53 | Active |
| US9095584B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 50 | Active |
| US9545397B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 48 | Active |
| US10813921B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 37 | Active |
| USRE48608E1 | Method to predict response to pharmacological chaperone treatment of diseases | General | 35 | Active |
| US11510997B2 | Treatment of primary ciliary dyskinesia with synthetic messenger RNA | Chemistry; Metallurgy | 4 | Active |
| US7829579B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | Emerging Cross-Sectional Technologies | 3 | Active |
| US11786610B2 | Treatment of primary ciliary dyskinesia with synthetic messenger RNA | Chemistry; Metallurgy | 2 | Active |
| US9119845B2 | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase | Emerging Cross-Sectional Technologies | 1 | Active |
| US12133923B2 | Lipid nanoparticle compositions and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US7964617B2 | Methods for treating parkinsons disease and parkinsonism | Emerging Cross-Sectional Technologies | 1 | Active |
| US11642421B2 | Treatment of primary ciliary dyskinesia with synthetic messenger RNA | Chemistry; Metallurgy | 1 | Active |
| US12337068B2 | Lipid nanoparticle compositions and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US9402837B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | Emerging Cross-Sectional Technologies | 0 | Active |
| US8883813B2 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | Emerging Cross-Sectional Technologies | 0 | Active |
| US12121610B2 | Compositions and methods for targeted delivery to cells | Chemistry; Metallurgy | 0 | Active |
| US9044437B2 | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases | Human Necessities | 0 | Active |
| US9931353B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | Human Necessities | 0 | Active |
| US12257318B2 | Polynucleotide compositions, related formulations, and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US9675627B2 | Dosing regimens for treating and/or preventing cerebral amyloidoses | Human Necessities | 0 | Active |
| US9597324B2 | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes | Emerging Cross-Sectional Technologies | 0 | Active |
| US10064851B2 | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.